Obesity‑Care Surge

Novo Nordisk AS reported 10 % sales growth and 6 % operating‑profit growth for 2025 at constant exchange rates. Obesity‑care revenue climbed from DKK 6 bn in 2019 to DKK 82 bn in 2025, a 31 % annual growth rate, while GLP‑1 sales expanded over 30 % in 2025. Wegovy generated DKK 28 bn in international sales, up 134 % versus the prior year, and Ozempic achieved DKK 31.83 bn in Q4, a 1 % increase. Rybelsus sales fell 19 % to DKK 5.30 bn, and the rare‑disease segment recorded flat DKK 5.35 bn. The company’s full‑year revenue totaled $46.81 bn, a 6 % rise in DKK and 10 % at constant exchange rates, yet it missed market revenue estimates.